1. Persistent Infection of Drug-resistant Influenza A Virus during Chemotherapy for Malignant Lymphoma
- Author
-
Kiyoshi Furuta, Fumihiro Kawakami, Naoto Kaneko, Hideyuki Nakazawa, Kiyoshi Kitano, Yukio Hirabayashi, Toru Kawakami, Yuto Mimura, Toshiro Ito, Rei Isobe, and Mami Shimazaki
- Subjects
0301 basic medicine ,Nasal cavity ,Male ,Oseltamivir ,Lymphoma ,viruses ,medicine.medical_treatment ,030106 microbiology ,Acids, Carbocyclic ,Neuraminidase ,Drug resistance ,Cyclopentanes ,medicine.disease_cause ,Antiviral Agents ,Guanidines ,Virus ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Refractory ,Drug Resistance, Viral ,Influenza, Human ,Internal Medicine ,medicine ,Influenza A virus ,Humans ,030212 general & internal medicine ,Aged, 80 and over ,Chemotherapy ,business.industry ,Influenza A Virus, H3N2 Subtype ,virus diseases ,General Medicine ,Virology ,medicine.anatomical_structure ,chemistry ,Immunology ,Mutation ,Peramivir ,business ,medicine.drug - Abstract
We herein report the case of an 80-year-old man with malignant lymphoma who became persistently infected with influenza A virus. Although he was repeatedly treated with NA inhibitors, such as oseltamivir or peramivir, nasal cavity swab tests for influenza A antigen continued to be positive for more than 2 months. Virological analyses revealed that he was infected with the NA inhibitor-resistant A (H3N2) virus possessing an R292K substitution in the NA protein. These findings suggest that a drug-resistant influenza virus strain might selectively survive antiviral therapy in elderly patients with refractory malignant lymphoma undergoing multiple chemotherapies. more...
- Published
- 2016